ClinicalTrials.gg
CompletedNCT02102490MONARCH 1Updated Jan 21, 2020Results posted

A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread

A Phase 2 interventional study of Abemaciclib in Metastatic Breast Cancer, sponsored by Eli Lilly and Company. Completed at 36 sites in 4 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-21.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
132
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.

Enrollment
26th of 55
132 · median 120
Started
2014
with 3 others
Phase 2
27 of 55
12 open now
Registered
2nd of 55
by date
Lead sponsor
17 of 55
Eli Lilly and Company

Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 26th largest by enrollment, is one of 4 that started in 2014, is one of 27 in phase 2, and was the 2nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing abemaciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate whether the study drug known as abemaciclib is effective in treating participants with breast cancer who have already tried other drug treatments.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

Keywords

  • Endocrine Therapy, Taxane, MONARCH 1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (-) breast cancer.
  • Recurrent, locally advanced, unresectable or breast cancer with disease progression following anti-estrogen therapy.
  • Prior treatment with at least 2 chemotherapy regimens:

    • At least 1 of these regimens must have been administered in the metastatic setting.
    • At least 1 of these regimens must have contained a taxane.
    • No more than 2 prior chemotherapy regimens in the metastatic setting.
  • Have a performance status (PS) of 0 to 1 on the scale.
  • Have discontinued all previous therapies for cancer.
  • Have the presence of measureable disease as defined by Version 1.1.

Exclusion criteria

Exclusion Criteria:

  • Have either a history of central nervous system (CNS) or evidence of on the magnetic resonance image of brain obtained at baseline.
  • Received prior therapy with another cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor.
  • Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug.
  • Have had major surgery within 14 days of the initial dose of study drug.
  • Have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    Abemaciclib

    200 milligrams (mg) abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.

    Drug: Abemaciclib

Interventions

  • Administered orally

    Also known as: LY2835219

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])

    ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

    Time frame: From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)

Secondary outcomes

  1. Overall Survival (OS)

    OS defined as the time from first dose date to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.

    Time frame: From Date of First Dose until Death Due to Any Cause (Up To 27 Months)

  2. Duration of Response (DOR)

    DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date.

    Time frame: From Date of CR, PR until Disease Progression or Death Due to Any Cause (Up To 14 Months)

  3. Progression Free Survival (PFS)

    PFS defined as the time from the first day of therapy to the first evidence of disease progression as defined by RECIST v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of first dose, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

    Time frame: From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 27 Months)

  4. Percentage of Participants With CR, PR or SD (Disease Control Rate [DCR])

    Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions.

    Time frame: From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)

  5. Percentage of Participants With Tumor Response of Stable Disease (SD) for at Least 6 Months, Partial Response (PR) or Complete Response (CR) (Clinical Benefit Rate)

    Clinical benefit rate defined as percentage of patients with best overall response of CR, PR, or SD with a duration of at least 6 months. CR, PR, or SD were defined using RECIST, v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Percentage of participants = (participants with CR+PR+SD with a duration of at least 6 months /number of participants enrolled) \*100.

    Time frame: From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)

  6. Number of Participants With Categorical Change From Baseline in Brief Pain Inventory Short Form (mBPI-sf) - Worst Pain Score

    A self-reported scale that measures the severity of pain based on the average pain experienced over the past 24 hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).

    Time frame: Cycle 6 Day 1

  7. Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) for Abemaciclib and Metabolites M2 and M20

    Area Under the Concentration versus Time Curve from Time Zero to Infinity (AUC\[0-∞\]) was evaluated for Abemaciclib and Metabolites M2 and M20

    Time frame: Cycle 1 Day 1 pre dose, Cycle 1 Day 15 4 hours (h) and 7 h post dose, Cycle 2 Day 1 pre dose and 3 h post dose, Cycle 3 Day1 pre dose

  8. Number of Participants With Categorical Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) - Global Health Status Score

    EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures 5 functional domains (physical, role, cognitive, emotional, and social), global health status, and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, higher scores represent a better level of functioning. For symptoms scales, higher scores represented a greater degree of symptoms.

    Time frame: Cycle 6 Day 1

07

Results

Posted Nov 30, 2017

Participant flow

Participant flow — Overall Study
MilestoneAbemaciclib
Started132
Received at least 1 dose of study drug132
Completed125
Not completed7
Withdrew: Death6
Withdrew: Lost to follow-up1

Outcome measures

PrimaryPercentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])

ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

Time frame:
From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])
Percentage of participantsAbemaciclib
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])19.7 (13.3 to 27.5)
SecondaryOverall Survival (OS)

OS defined as the time from first dose date to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.

Time frame:
From Date of First Dose until Death Due to Any Cause (Up To 27 Months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsAbemaciclib
Overall Survival (OS)22.32 (17.72 to NA)
SecondaryDuration of Response (DOR)

DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date.

Time frame:
From Date of CR, PR until Disease Progression or Death Due to Any Cause (Up To 14 Months)
Reported as:
Median · Months
Duration of Response (DOR)
MonthsAbemaciclib
Duration of Response (DOR)8.6 (5.8 to 10.2)
SecondaryProgression Free Survival (PFS)

PFS defined as the time from the first day of therapy to the first evidence of disease progression as defined by RECIST v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of first dose, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

Time frame:
From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 27 Months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsAbemaciclib
Progression Free Survival (PFS)6.0 (4.2 to 7.5)
SecondaryPercentage of Participants With CR, PR or SD (Disease Control Rate [DCR])

Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions.

Time frame:
From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants With CR, PR or SD (Disease Control Rate [DCR])
Percentage of participantsAbemaciclib
Percentage of Participants With CR, PR or SD (Disease Control Rate [DCR])67.4 (58.7 to 75.3)
SecondaryPercentage of Participants With Tumor Response of Stable Disease (SD) for at Least 6 Months, Partial Response (PR) or Complete Response (CR) (Clinical Benefit Rate)

Clinical benefit rate defined as percentage of patients with best overall response of CR, PR, or SD with a duration of at least 6 months. CR, PR, or SD were defined using RECIST, v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Percentage of participants = (participants with CR+PR+SD with a duration of at least 6 months /number of participants enrolled) \*100.

Time frame:
From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Tumor Response of Stable Disease (SD) for at Least 6 Months, Partial Response (PR) or Complete Response (CR) (Clinical Benefit Rate)
Percentage of participantsAbemaciclib
Percentage of Participants With Tumor Response of Stable Disease (SD) for at Least 6 Months, Partial Response (PR) or Complete Response (CR) (Clinical Benefit Rate)42.4 (33.9 to 51.3)
SecondaryNumber of Participants With Categorical Change From Baseline in Brief Pain Inventory Short Form (mBPI-sf) - Worst Pain Score

A self-reported scale that measures the severity of pain based on the average pain experienced over the past 24 hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).

Time frame:
Cycle 6 Day 1
Reported as:
Count of participants · Participants
Number of Participants With Categorical Change From Baseline in Brief Pain Inventory Short Form (mBPI-sf) - Worst Pain Score
ParticipantsAbemaciclib
Better18
No Change21
Worse20
SecondaryPharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) for Abemaciclib and Metabolites M2 and M20

Area Under the Concentration versus Time Curve from Time Zero to Infinity (AUC\[0-∞\]) was evaluated for Abemaciclib and Metabolites M2 and M20

Time frame:
Cycle 1 Day 1 pre dose, Cycle 1 Day 15 4 hours (h) and 7 h post dose, Cycle 2 Day 1 pre dose and 3 h post dose, Cycle 3 Day1 pre dose
Reported as:
Geometric mean · Nanograms*hour/milliliters (ng*h/mL)]
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) for Abemaciclib and Metabolites M2 and M20
Nanograms*hour/milliliters (ng*h/mL)]Abemaciclib
Abemaciclib3510 ± 38.0
M21620 ± 55.0
M202750 ± 55.0
SecondaryNumber of Participants With Categorical Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) - Global Health Status Score

EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures 5 functional domains (physical, role, cognitive, emotional, and social), global health status, and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, higher scores represent a better level of functioning. For symptoms scales, higher scores represented a greater degree of symptoms.

Time frame:
Cycle 6 Day 1
Reported as:
Count of participants · Participants
Number of Participants With Categorical Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) - Global Health Status Score
ParticipantsAbemaciclib
Better17
No Change16
Worse26

Adverse events

Collected over Up To 45.57 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abemaciclib—33/132 (25%)132/132 (100%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventAbemaciclib
NauseaGastrointestinal disorders3/132
Blood creatinine increasedInvestigations3/132
DehydrationMetabolism and nutrition disorders3/132
Abdominal painGastrointestinal disorders2/132
CellulitisInfections and infestations2/132
DyspnoeaRespiratory, thoracic and mediastinal disorders2/132
Pleural effusionRespiratory, thoracic and mediastinal disorders2/132
Febrile neutropeniaBlood and lymphatic system disorders1/132
HaematotoxicityBlood and lymphatic system disorders1/132
NeutropeniaBlood and lymphatic system disorders1/132
Most frequent other events
Showing 10 of 48
Most frequent other events
EventAbemaciclib
DiarrhoeaGastrointestinal disorders120/132
NauseaGastrointestinal disorders89/132
FatigueGeneral disorders63/132
Decreased appetiteMetabolism and nutrition disorders60/132
VomitingGastrointestinal disorders46/132
AnaemiaBlood and lymphatic system disorders35/132
Abdominal painGastrointestinal disorders34/132
AstheniaGeneral disorders31/132
Neutrophil count decreasedInvestigations31/132
CoughRespiratory, thoracic and mediastinal disorders28/132

Baseline characteristics

All enrolled participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(Years)Abemaciclib
Mean59.13 ± 10.33
Sex: Female, Male
Sex: Female, Male(Participants)Abemaciclib
Female132
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Abemaciclib
Hispanic or Latino8
Not Hispanic or Latino112
Unknown or Not Reported12
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Abemaciclib
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American6
White112
More than one race0
Unknown or Not Reported12
Region of Enrollment
Region of Enrollment(Participants)Abemaciclib
Belgium28
United States70
France11
Spain23
08

Study locations

36 sites
  • Northern Arizona Hematology & Oncology Associates
    Sedona, Arizona 86336, United States
  • HOPE Hematology Oncology Physicians and Extenders
    Tucson, Arizona 85704, United States
  • Arizona Clinical Research Center
    Tucson, Arizona 85715, United States
  • Univ of California San Francisco
    San Francisco, California 94115, United States
  • Sansum Medical Research Foundation
    Santa Barbara, California 93105, United States
  • Rocky Mountain Cancer Center
    Denver, Colorado 80220, United States
  • Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33916, United States
  • Advanced Medical Specialties
    Miami, Florida 33176, United States
  • Florida Cancer Specialists
    Saint Petersburg, Florida 33705, United States
  • Maryland Oncology Hematology, P.A.
    Columbia, Maryland 21044, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Minnesota Oncology/Hematology PA
    Minneapolis, Minnesota 55404, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Oncology Hematology Care Inc
    Cincinnati, Ohio 45242, United States
  • Sarah Cannon Research Institute SCRI
    Nashville, Tennessee 37203, United States
  • Texas Oncology Cancer Center
    Austin, Texas 78731, United States
  • Texas Oncology - Bedford
    Bedford, Texas 76022, United States
  • Presbyterian Hospital Dallas
    Dallas, Texas 75231, United States
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • The Center for Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • Texas Oncology-Memorial City
    Houston, Texas 77024, United States
  • Texas Oncology-Plano West
    Plano, Texas 75093, United States
  • Texas Oncology-Sherman
    Sherman, Texas 75090-0504, United States
  • US Oncology
    The Woodlands, Texas 77380, United States
  • Tyler Cancer Center
    Tyler, Texas 75702, United States
  • Northwest Cancer Specialists PC
    Vancouver, Washington 98684, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brussel, 1000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Charleroi, 6000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leuven, 3000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Liège, 4000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dijon, 21034, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris, 75248, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08035, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28007, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Valencia, 46015, Spain
09

References and documents

Publications

  • Dickler MN, Tolaney SM, Rugo HS, Cortes J, Dieras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017 Sep 1;23(17):5218-5224. doi: 10.1158/1078-0432.CCR-17-0754. Epub 2017 May 22. Erratum In: Clin Cancer Res. 2018 Nov 1;24(21):5485. doi: 10.1158/1078-0432.CCR-18-3193. PubMed 28533223 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Apr 2016, 22 months.

Results were first posted in Nov 2017, 1 year 7 months after primary completion. A results delay was requested in Aug 2016.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 22 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2014
First posted
Apr 3, 2014
StartActual
Jun 10, 2014
Primary completionActual
Apr 30, 2016
CompletionActual
Oct 22, 2018
Results delay requested
Aug 13, 2016
Results first posted
Nov 30, 2017
Last update
Jan 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02102490
Responsible party
Sponsor
First posted
Apr 3, 2014
Start date
Jun 10, 2014
Primary completion
Apr 30, 2016
Completion
Oct 22, 2018
Results posted
Nov 30, 2017
Last update
Jan 21, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion